We are a specialty pharmaceutical company that develops, markets and sells, and are a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems and related products in the physician-dispensed market. Obagi systems and products are designed to prevent or improve the most common and visible skin disorders in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, facial redness, and soft tissue deficits, such as fine lines and wrinkles. Our products have been developed to enhance the underlying health of patients’ skin, and clinical studies have demonstrated that the use of our systems results in skin that looks and acts younger and healthier.
Company profile
Ticker
OMPI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
954658730
Latest filings (excl ownership)
15-12B
Securities registration termination
6 May 13
8-K
Completion of Acquisition or Disposition of Assets
26 Apr 13
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Apr 13
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Apr 13
25-NSE
Exchange delisting
25 Apr 13
SC 14D9/A
Tender offer solicitation (amended)
25 Apr 13
SC TO-T/A
Third party tender offer statement (amended)
25 Apr 13
10-K/A
2013 FY
Annual report (amended)
24 Apr 13
SC 14D9/A
Tender offer solicitation (amended)
24 Apr 13
SC TO-T/A
Third party tender offer statement (amended)
24 Apr 13
Latest ownership filings
SC 13D/A
GAMCO INVESTORS, INC. ET AL
13 May 13
SC 13D/A
GAMCO INVESTORS, INC. ET AL
17 Apr 13
SC 13D
GAMCO INVESTORS, INC. ET AL
28 Mar 13
SC 13D/A
DISCOVERY EQUITY PARTNERS, LP
13 Jan 12
SC 13D/A
DISCOVERY EQUITY PARTNERS, LP
22 Dec 11
SC 13D/A
DISCOVERY EQUITY PARTNERS, LP
15 Nov 11
SC 13D/A
DISCOVERY EQUITY PARTNERS, LP
30 Mar 10